- Home
- NSTS vs PYXS Comparison
NSTS vs PYXS Comparison
Compare NSTS & PYXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NSTS | PYXS |
|---|---|---|
| Founded | 1921 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 60.2M | 71.6M |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | NSTS | PYXS |
|---|---|---|
| Price | $12.00 | $1.55 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $6.75 |
| AVG Volume (30 Days) | 3.6K | ★ 297.0K |
| Earning Date | 03-27-2026 | 03-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 28.65 |
| EPS | ★ N/A | N/A |
| Revenue | $256,000.00 | ★ $16,146,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $10.73 | $0.84 |
| 52 Week High | $13.06 | $5.55 |
Technical Indicators
Market Signals| Indicator | NSTS | PYXS |
|---|---|---|
| Relative Strength Index (RSI) | 38.21 | 49.36 |
| Support Level | $11.85 | $1.29 |
| Resistance Level | $12.30 | $1.69 |
| Average True Range (ATR) | 0.12 | 0.11 |
| MACD | -0.03 | 0.02 |
| Stochastic Oscillator | 0.00 | 52.70 |
Price Performance
Historical ComparisonAbout NSTS NSTS Bancorp Inc.
NSTS Bancorp Inc is a savings and loan holding company regulated Federal Reserve Board. The company was formed to serve as the North Shore Trust and Savings stock holding company. The Bank is a wholly-owned subsidiary of the company and operates as a traditional savings institution focused on serving the banking needs of customers in market area of Lake County, Illinois and adjacent communities.
About PYXS Pyxis Oncology Inc.
Pyxis Oncology Inc is a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. It develops the product candidates with the objective to directly kill tumor cells, and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion.